Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2012-04-20 | Michael A. Griffith has served as a Director of Repligen since April 2012. Mr. Griffith is currently the Chief Executive Officer and a director at Laureate Biopharmaceutical Services, Inc., a full-service contract manufacturing organization focused on the production and manufacture of biologic drugs. Prior to joining Laureate Biopharmaceutical Services in April 2010, he was on the board of directors at Centrue Financial Corporation and its subsidiary, Centrue Bank, a NASDAQ-listed commercial bank, from 2002 to March 2010. Mr. Griffith was the founder of Aptuit, Inc., a global contract pharmaceutical research, development and manufacturing company, and from 2004 to 2008 served as the company’s CEO. From 1996 to 2000, Mr. Griffith was with ChiRex, Inc., where he initially served as CFO before being named the company’s Chairman and CEO. Mr. Griffith was part of the team that led the initial public offering for ChiRex, which was later sold for $600 million to Rhodia SA, a NYSE-listed, Paris-based specialty chemicals company. Prior to his involvement in the biopharmaceutical industry, Mr. Griffith worked for nearly 15 years as a commercial and investment banker at Bankers Trust and First Boston. He earned a Masters of Management from the Kellogg Graduate School of Management at Northwestern University, and a B.S. in business administration from the University of Kansas. The Board of Directors believes Mr. Griffith’s qualifications to sit on the Board of Directors include his extensive experience in the areas of pharmaceutical development and manufacturing and his financial experience. |
| 2013-04-09 | Michael A. Griffith has served as a Director of Repligen since April 2012. ... The Compensation Committee, of which Mr. Cooper, Mr. Griffith (who replaced Mr. Goldberg on the Compensation Committee in March 2013) and Mr. Henry are currently members. ... The Science and Technology Committee of the Board consists currently of Messrs. Goldberg, Griffith, Henry, and Herlihy. ... Director Compensation Table for the Fiscal Year Ended December 31, 2012: Michael A. Griffith: Fees Earned or Paid in Cash $26,250, Option Awards $56,820, Total $83,070. |
| 2014-04-08 | Michael A. Griffith (1)(3) 55 Director; Member of the Compensation Committee; Member of the Nominating and Corporate Governance Committee; Director Compensation Table for the Fiscal Year Ended December 31, 2013: Michael A. Griffith Fees Earned or Paid in Cash $44,000, Stock Awards $50,001, Total $94,001. |
| 2015-04-17 | Michael A. Griffith has served as a director of Repligen since April 2012. ... The Compensation Committee, of which Dr. Cooper, Mr. Griffith and Mr. Barthelemy (who replaced Dr. Goldberg on the Compensation Committee in December 2014) are currently members ... The Nominating and Corporate Governance Committee of the Board of Directors consists currently of Ms. Dawes, Chairperson, Mr. Griffith and Mr. Ryan. ... Director Compensation Table for the Fiscal Year Ended December 31, 2014 ... Michael A. Griffith 45,000 Fees Earned or Paid in Cash ($) 35,008 Stock Awards ($) 34,958 Option Awards ($) Total 114,966 |
Data sourced from SEC filings. Last updated: 2025-08-30